kabutan

Veritas In Silico Inc.(130A) Summary

130A
TSE Growth
Veritas In Silico Inc.
482
JPY
+1
(+0.21%)
Jan 29, 3:30 pm JST
3.15
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.63
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
482 JPY 3.14 USD
Previous Close Jan 28
481 JPY 3.15 USD
High Jan 29, 9:00 am
483 JPY 3.15 USD
Low Jan 29, 10:37 am
470 JPY 3.06 USD
Volume
101,600
Trading Value
0.05B JPY 0.32M USD
VWAP
476.33 JPY 3.11 USD
Minimum Trading Value
48,200 JPY 315 USD
Market Cap
3.13B JPY 0.02B USD
Number of Trades
213
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
416
1-Year High Jul 31, 2025
10,270
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 1,300 513,600 395.08
Jan 16, 2026 0 498,100
Jan 9, 2026 0 488,600
Dec 26, 2025 0 474,600
Dec 19, 2025 0 333,300
Company Profile
Veritas In Silico operates a platform business for small molecule and nucleic acid drug discovery targeting mRNA.
Sector
Pharmaceuticals
Veritas In Silico Inc. is a Japan-based bio-pharmaceutical company. The company develops a platform for small molecule and nucleic acid drug discovery, specializing in targeting mRNA. It focuses on diseases that cannot be addressed by conventional protein-targeted drug discovery approaches. Using their proprietary in silico RNA structure analysis technology, Veritas In Silico has realized a drug discovery approach that targets partial structures on mRNA. This enables the creation of pharmaceuticals that address unmet medical needs. The company collaborates with multiple pharmaceutical companies, promoting joint research based on their drug discovery platform "ibVIS". By targeting mRNA, Veritas In Silico aims to open up new possibilities in the field of drug discovery and development.